Liquidia Technologies Inc (LQDA)
🔔 Watch stock
Appears in These Scanners
This stock currently matches 25 of our scanner strategies — each hit links to the scanner.
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. Scanners marked in red are red-flag signals (risk/short scanners) — appearing there is not a seal of approval. View all scanners
Basics
Performance
Valuation
Profitability
Balance Sheet & Safety
Growth
Quality & Screener
AI Rating
NeutralLiquidia ist ein Biopharma-Unternehmen (Inhalationstherapie YUTREPIA gegen Lungenhochdruck PAH/PH-ILD); in den sechs geprüften Filings gibt es keine KI-Umsatzquelle, keinen belegten operativen KI-Einsatz und kein konkretes KI-Geschäftsrisiko fürs eigene Geschäftsmodell — KI erscheint ausschließlich als generischer IT-Risikoabsatz im Konjunktiv („We … may adopt, use or incorporate artificial intelligence technology … into the information technology systems or software that we use“, also nur ein mögliches künftiges Einführen) samt allgemeinem Verweis auf die KI-Regulierungslandschaft (EU AI Act, SEC-Fokus auf „AI-washing“), nahezu wortgleich in allen vier 10-Qs und beiden 10-Ks; im jüngsten 10-K (05.03.2026) und sämtlichen 10-Qs taucht KI außerhalb dieses Boilerplate-Risikoabschnitts nicht auf.
View the full file — quotes, sources, reviewed filings
Filings Reviewed: 10-Q 2026-05-11 · 10-Q 2025-11-03 · 10-Q 2025-08-12 · 10-Q 2025-05-08 · 10-K 2026-03-05 · 10-K 2025-03-19
Rated on July 8, 2026 · How the Rating Is Built
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | -0.45 | – | 3 | -35.60 | -1,315.40 | -21 | -26 |
| 2025: Q1 | -0.45 | – | 3 | 5.00 | -1,229.70 | -31 | -31 |
| 2025: Q2 | -0.49 | – | 9 | 141.50 | -470.50 | -40 | -41 |
| 2025: Q3 | -0.04 | – | 54 | 1,121.70 | -6.50 | -10 | -11 |
| 2025: Q4 | 0.15 | – | 92 | 3,054.60 | 15.80 | 44 | 42 |
| 2026: Q1 | 0.52 | – | 133 | 4,158.50 | 39.80 | 53 | 50 |
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
About the Company
Liquidia Corporation, ein biopharmazeutisches Unternehmen, entwickelt, fertigt und vermarktet verschiedene Produkte für seltene kardiopulmonale Erkrankungen in den USA. Zu den führenden Produktkandidaten zählt YUTREPIA, eine inhalative Trockenpulverformulierung von Treprostinil zur Behandlung von pu…
| CEO Insider Trades (12 Mo.) | selling own stock |
|---|---|
| Employees | 216 |
| Headquarters | Morrisville, NC |
| Website | liquidia.com |
| IPO Date | 26. Jul 2018 |
| Next Earnings | 11. Aug 2026 |
Management
| Name | Title | Birth Year |
|---|---|---|
| Roger A. Jeffs Ph.D. | CEO & Director | 1962 |
| Michael Kaseta | COO & CFO | 1976 |
| Russell Schundler | General Counsel & Corporate Secretary | 1976 |
| Scott Moomaw | Chief Commercial Officer | 1971 |
| Rajeev Saggar M.D. | Chief Medical Officer | 1975 |
| Dana Boyle | Chief Accounting Officer | 1985 |
| Christian Perez Font | Senior VP, Chief Compliance Officer & Associate General Counsel | – |
| Michael Post | Senior Vice President of Marketing | – |
| Matt Snow | Senior Vice President of Sales | – |
| Sarah Krepp SPHR | Chief Human Resources Officer | 1982 |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Chart
Interactive price chart (TradingView).
Data as of: July 20, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.